134 related articles for article (PubMed ID: 35085770)
21. LncRNA-MALAT1 Regulates Cancer Glucose Metabolism in Prostate Cancer via MYBL2/mTOR Axis.
Mu X; Shen Z; Lin Y; Xiao J; Xia K; Xu C; Chen B; Shi R; Zhu A; Sun X; Tao T; Song X; Xuan Q
Oxid Med Cell Longev; 2022; 2022():8693259. PubMed ID: 35557985
[TBL] [Abstract][Full Text] [Related]
22. HOTAIR-mediated reciprocal regulation of EZH2 and DNMT1 contribute to polyphyllin I-inhibited growth of castration-resistant prostate cancer cells in vitro and in vivo.
Xiang S; Zou P; Tang Q; Zheng F; Wu J; Chen Z; Hann SS
Biochim Biophys Acta Gen Subj; 2018 Mar; 1862(3):589-599. PubMed ID: 29221985
[TBL] [Abstract][Full Text] [Related]
23. Long noncoding RNA MALAT1 enhances the docetaxel resistance of prostate cancer cells via miR-145-5p-mediated regulation of AKAP12.
Xue D; Lu H; Xu HY; Zhou CX; He XZ
J Cell Mol Med; 2018 Jun; 22(6):3223-3237. PubMed ID: 29633510
[TBL] [Abstract][Full Text] [Related]
24. MALAT1 Is Associated with Poor Response to Oxaliplatin-Based Chemotherapy in Colorectal Cancer Patients and Promotes Chemoresistance through EZH2.
Li P; Zhang X; Wang H; Wang L; Liu T; Du L; Yang Y; Wang C
Mol Cancer Ther; 2017 Apr; 16(4):739-751. PubMed ID: 28069878
[TBL] [Abstract][Full Text] [Related]
25. MiR-605-3p inhibits malignant progression of prostate cancer by up-regulating EZH2.
Pan MZ; Song YL; Gao F
Eur Rev Med Pharmacol Sci; 2019 Oct; 23(20):8795-8805. PubMed ID: 31696466
[TBL] [Abstract][Full Text] [Related]
26. Unveiling the non-canonical functions of EZH2 in prostate cancer.
Yi Y; Li Y; Chen K; Cao Q
Oncotarget; 2023 Feb; 14():127-128. PubMed ID: 36780304
[No Abstract] [Full Text] [Related]
27. Posttranscriptional silencing of the lncRNA MALAT1 by miR-217 inhibits the epithelial-mesenchymal transition via enhancer of zeste homolog 2 in the malignant transformation of HBE cells induced by cigarette smoke extract.
Lu L; Luo F; Liu Y; Liu X; Shi L; Lu X; Liu Q
Toxicol Appl Pharmacol; 2015 Dec; 289(2):276-85. PubMed ID: 26415832
[TBL] [Abstract][Full Text] [Related]
28. Non-SMC condensin I complex subunit D2 and non-SMC condensin II complex subunit D3 induces inflammation
Yuan CW; Sun XL; Qiao LC; Xu HX; Zhu P; Chen HJ; Yang BL
World J Gastroenterol; 2019 Dec; 25(47):6813-6822. PubMed ID: 31885422
[TBL] [Abstract][Full Text] [Related]
29. Pharmacological inhibition of noncanonical EED-EZH2 signaling overcomes chemoresistance in prostate cancer.
Li X; Gera L; Zhang S; Chen Y; Lou L; Wilson LM; Xie ZR; Sautto G; Liu D; Danaher A; Mamouni K; Yang Y; Du Y; Fu H; Kucuk O; Osunkoya AO; Zhou J; Wu D
Theranostics; 2021; 11(14):6873-6890. PubMed ID: 34093859
[No Abstract] [Full Text] [Related]
30. MicroRNA-144 Suppresses Prostate Cancer Growth and Metastasis by Targeting EZH2.
Sun XB; Chen YW; Yao QS; Chen XH; He M; Chen CB; Yang Y; Gong XX; Huang L
Technol Cancer Res Treat; 2021; 20():1533033821989817. PubMed ID: 33550923
[TBL] [Abstract][Full Text] [Related]
31. STAT3/HOTAIR Signaling Axis Regulates HNSCC Growth in an EZH2-dependent Manner.
Sun S; Wu Y; Guo W; Yu F; Kong L; Ren Y; Wang Y; Yao X; Jing C; Zhang C; Liu M; Zhang Y; Zhao M; Li Z; Wu C; Qiao Y; Yang J; Wang X; Zhang L; Li M; Zhou X
Clin Cancer Res; 2018 Jun; 24(11):2665-2677. PubMed ID: 29540490
[No Abstract] [Full Text] [Related]
32. Effect of m6A methyltransferase METTL3 -mediated MALAT1/E2F1/AGR2 axis on adriamycin resistance in breast cancer.
Li S; Jiang F; Chen F; Deng Y; Pan X
J Biochem Mol Toxicol; 2022 Jan; 36(1):e22922. PubMed ID: 34964205
[TBL] [Abstract][Full Text] [Related]
33. BRCA1 and EZH2 cooperate in regulation of prostate cancer stem cell phenotype.
Gorodetska I; Lukiyanchuk V; Peitzsch C; Kozeretska I; Dubrovska A
Int J Cancer; 2019 Dec; 145(11):2974-2985. PubMed ID: 30968962
[TBL] [Abstract][Full Text] [Related]
34. MALAT1 long ncRNA promotes gastric cancer metastasis by suppressing PCDH10.
Qi Y; Ooi HS; Wu J; Chen J; Zhang X; Tan S; Yu Q; Li YY; Kang Y; Li H; Xiong Z; Zhu T; Liu B; Shao Z; Zhao X
Oncotarget; 2016 Mar; 7(11):12693-703. PubMed ID: 26871474
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of EZH2 via the STAT3/HOTAIR signalling axis contributes to cell cycle arrest and apoptosis induced by polyphyllin I in human non-small cell lung cancer cells.
Li HS; Xu Y
Steroids; 2020 Dec; 164():108729. PubMed ID: 32941921
[TBL] [Abstract][Full Text] [Related]
36. lncRNA HCP5 acts as a ceRNA to regulate EZH2 by sponging miR‑138‑5p in cutaneous squamous cell carcinoma.
Zou S; Gao Y; Zhang S
Int J Oncol; 2021 Aug; 59(2):. PubMed ID: 34195851
[TBL] [Abstract][Full Text] [Related]
37. Conditionally replicative adenovirus carrying shRNA targeting EZH2 inhibits prostate cancer growth and invasion.
Xu SG; Yu JJ; Shi Q; Niu Q; Guo Z; Guo BY; Zhou GC; Gu X; Wu YX
Oncol Rep; 2019 Jul; 42(1):273-282. PubMed ID: 31115564
[TBL] [Abstract][Full Text] [Related]
38. LncRNA MALAT1 Regulates USP22 Expression Through EZH2-Mediated H3K27me3 Modification to Accentuate Sepsis-Induced Myocardial Dysfunction.
Xu H; Ye W; Shi B
Cardiovasc Toxicol; 2022 Sep; 22(9):813-830. PubMed ID: 35726125
[TBL] [Abstract][Full Text] [Related]
39. Activation of EZH2 and SUZ12 Regulated by E2F1 Predicts the Disease Progression and Aggressive Characteristics of Bladder Cancer.
Lee SR; Roh YG; Kim SK; Lee JS; Seol SY; Lee HH; Kim WT; Kim WJ; Heo J; Cha HJ; Kang TH; Chung JW; Chu IS; Leem SH
Clin Cancer Res; 2015 Dec; 21(23):5391-403. PubMed ID: 26268246
[TBL] [Abstract][Full Text] [Related]
40. Targeting of EZH2 inhibits epithelial‑mesenchymal transition in head and neck squamous cell carcinoma via regulating the STAT3/VEGFR2 axis.
Zhao M; Hu X; Xu Y; Wu C; Chen J; Ren Y; Kong L; Sun S; Zhang L; Jin R; Zhou X
Int J Oncol; 2019 Nov; 55(5):1165-1175. PubMed ID: 31545422
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]